期刊文献+

贝伐单抗在青光眼滤过性手术应用的研究进展

Bevacizumab application in glaucoma filtering surgery
原文传递
导出
摘要 滤过泡瘢痕化是导致青光眼滤过性手术失败的主要因素,目前研究已证实血管内皮生长因子(vascularendothelialgrowthfactor,VEGF)在促进血管生成、创伤愈合、瘢痕形成中起重要作用。近年来眼科学者将VEGF抑制剂贝伐单抗(bevacizumab)作为抗瘢痕形成辅助用药用于青光眼滤过性手术,证实其对促进功能性滤过泡形成、控制眼压有较好的疗效,从而提高了手术成功率。本文就贝伐单抗在青光眼滤过性手术中的基础研究和临床应用等方面的研究进展作一综述。(国际眼科纵览,2012,36:298—301) Filtering bleb scarring is the main determinant factor leading to the failure of glaucoma filtering surgery. The vascular endothelial growth factor (VEGF) has been proved to be a significant role in the process of angiogenesis, wound healing and scar formation. In recent years, ophthalmologists have ap- plied VEGF inhibitor bevacizumab to glaucoma filtering surgery as an adjunct for inhibiting postoperative scarring, which shows good effect to promote the functioning bleb formation, control the intraocular pressure, thereby improve surgical outcome. This article reviewed the experimental study and clinical application of VEGF inhibitor bevacizumab in glaucoma filtering surgery. (Int Rev Ophthalmol, 2012, 36:298-301 )
出处 《国际眼科纵览》 2012年第5期298-301,共4页 International Review of Ophthalmology
关键词 青光眼 外科学 血管内皮生长因子 贝伐单抗 glaucoma/surgery vascular endothelial growth factor bevaeizumab
  • 相关文献

参考文献30

  • 1Ferrara N, Henzel WJ. Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells. Biochem Biophys Res Commun, 1989, 161 : 851-858.
  • 2Wilgus TA, Ferreira AM, Oberyszyn TM, et al. Regulation of scar formation by vascular endothelial growth factor. Lab Invest, 2008, 88 : 579-590.
  • 3Wynn TA. Cellular and molecular mechanisms of fibrosis. J Pathol, 2008, 214: 199-210.
  • 4Iwabe S, Lamas M, Vasquez PCG, et al. Aqueous humor endothelin-1 (Et-1), vascular endothelial growth factor (VEGF) and cyclooxygenase-2 (COX-2) levels in Mexican glaucomatous patients. Curr Eye Res, 2010, 35 : 287-294.
  • 5Park HY, Kim JH, Ahn MD, et al. Level of vascular endothelial growth factor in tenon tissue and results of glaucoma surgery. Arch Ophthalmol, 2012, 130: 685-689.
  • 6Li Z, Van Bergen T, Van de Veire S, et al. Inhibition of vascular endothelial growth factor reduces scar formation after glaucoma filtration surgery. Invest Ophthalmol Vis Sci, 2009, 50: 5217- 5225.
  • 7Hu DN, Ritch R, Liebmann J, et al. Vascular endothelial growth factor is increased in aqueous humor of glaucomatous eyes. J Glaucoma, 2002, 11 : 406-410.
  • 8Braghiroli MI, Sabbaga J, Hoff PM. Bevacizumab : overview of the literature. Expert Rev Anticancer Ther, 2012, 12: 567-580.
  • 9Kramer I, Lipp HP. Bevacizumab, a humanized anti-angiogenic monoclonal antibody for the treatment of colorectal cancer. J Clin Pharm Ther, 2007, 32 : 1-14.
  • 10Wong J, Wang N, Miller JW, et al. Modulation of human fibroblast activity by selected angiogenesis inhibitors. Exp Eye Res, 1994, 58: 439-451.

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部